Allergan
Allergan, officially known as Allergan plc, is a prominent global pharmaceutical company headquartered in the United States. Founded in 1948, Allergan has established itself as a leader in the biopharmaceutical industry, focusing on areas such as medical aesthetics, eye care, and neuroscience. The company is renowned for its innovative products, including the widely recognised Botox, which has transformed both cosmetic and therapeutic treatments. With major operational regions spanning North America, Europe, and Asia, Allergan has achieved significant milestones, including its acquisition by AbbVie in 2020, further solidifying its market position. The company’s commitment to research and development has led to a diverse portfolio of unique offerings, making it a key player in enhancing patient outcomes and quality of life.
DitchCarbon Score
How does Allergan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan's score of 33 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan's reported carbon emissions
In 2017, Allergan reported total greenhouse gas emissions of approximately 250,000,000 kg CO2e across all scopes, with specific emissions of about 88,190,000 kg CO2e from Scope 1 and approximately 46,800,000 kg CO2e from Scope 2 (market-based). The company has consistently disclosed emissions data for Scopes 1, 2, and 3 from 2013 onwards, demonstrating a commitment to transparency in its climate impact. Allergan's emissions have shown fluctuations over the years, with a notable increase in Scope 1 emissions from about 23,423,000 kg CO2e in 2010 to 88,190,000 kg CO2e in 2017. However, the company has not set specific reduction targets or initiatives as part of its climate commitments, indicating a potential area for improvement in its sustainability strategy. Overall, Allergan's emissions data reflects its operational footprint, but the absence of defined reduction targets suggests that the company may need to enhance its climate action plans to align with industry standards and expectations for corporate responsibility in addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
